このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

新生児発症型OTC欠損症(OTC-HOPE)を有する生後9か月未満の男児を対象としたECUR-506を調査する非盲検試験

2026年9月29日 更新者:iECURE, Inc.

遺伝的に新生児発症が確認された生後9か月未満の男性におけるECUR-506の単回静脈内(IV)投与の安全性と有効性を評価する第I/II相ファーストインヒト非盲検用量漸増研究オルニチントランスカルバミラーゼ (OTC) 欠損症

Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.

This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.

調査の概要

詳細な説明

The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is an approach used to repair, replace, or introduce functional copies of genes that are not working properly. ECUR-506 contains a functional copy of the OTC gene, along with a gene to encode an editing enzyme that enables insertion of the OTC gene into the genome. The study drug is administered as a single IV infusion. Because genes cannot enter cells on their own, ECUR-506 uses a delivery system based on adeno-associated virus (AAV), a commonly used viral vector, to transport the genetic material into cells.

研究の種類

介入

入学 (推定)

20

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Los Angeles、California、アメリカ、90095
        • UCLA Mattel Children's Hospital
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • Children's Hospital of Colorado, Anshutz Medical Campus
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Emory University School of Medicine
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • New York
      • New York、New York、アメリカ、10029
        • Icahn School of Medicine at Mount Sinai
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • Oregon Health and Science University
      • London、イギリス
        • Great Ormond Street Hospital
      • Newcastle upon Tyne、イギリス
        • The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital
    • New South Wales
      • Sydney、New South Wales、オーストラリア
        • The Children's Hospital at Westmead
    • Victoria
      • Melbourne、Victoria、オーストラリア、3052
        • The Royal Children's Hospital
      • Barcelona、スペイン、08950
        • Hopsital Sant Joan de Deu
      • Madrid、スペイン、28041
        • Hospital Universitario 12 de Octubre

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1日~7ヶ月 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

Key Inclusion Criteria:

  1. Male sex
  2. Gestational or adjusted (corrected) gestational age ≥ 37 weeks
  3. Age at screening is 24 hours to 7 months
  4. Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
  5. Has received age-appropriate vaccinations
  6. Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
  7. Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
  8. Current or historical biochemical profile consistent with OTCD
  9. Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.

Key Exclusion Criteria:

  1. Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
  2. Requiring urgent liver transplant due to liver failure as assessed by the PI.
  3. Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
  4. Known or suspected major organ injury/dysfunction/anomalies.
  5. Vital sign and laboratory abnormalities outside of reference ranges.
  6. Treatment with any other gene therapy or gene editing therapy
  7. Co-enrollment in any other study unless approved by the sponsor.
  8. Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
  9. Documented vertical transmission of HepA/HepB/HepC
  10. Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Low Dose Level

Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion.

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

実験的:Intermediate Dose Level

Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

実験的:High Dose Level

Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion.

ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness)
時間枠:Over 24 weeks post infusion

Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, Pediatric Neurologist exam parameters, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period.

AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related.

Over 24 weeks post infusion
Physical exam parameters
時間枠:Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI assessment of General Appearance, Dermatological, HEENT, Lymphatic, Respiratory, Cardiovascular, Gastrointestinal, Musculoskeletal, Neurological (Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes))

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Vital sign parameters
時間枠:Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI assessment of Systolic Blood Pressure, Diastolic Blood Pressure, Pulse Rate, Respiratory Rate, Temperature)

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Pediatric neurologist exam parameters
時間枠:Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes Pediatric Neurologist assessment of Neurological status by review of Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes.)

Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests
時間枠:as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Blood Safety tests to be reviewed in relation to established normal ranges for each assessment for the applicable age group)

as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Urinalysis evaluations
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period.

AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
12 lead ECG parameters
時間枠:as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.

Safety- (Includes PI review of Heart Rate, PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval, Overall Interpretation)

as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
Complete clinical response
時間枠:Over 24 weeks post infusion

Discontinuation of scavenger medication for a minimum duration of 28 days without reductions in prescribed daily protein intake during this time period by end of study.

Over 24 weeks post infusion

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of HAEs/person-year
時間枠:Day 1 post dose through Week 24

Key Secondary Endpoint: Pharmacodynamics and Efficacy

Day 1 post dose through Week 24
qPCR measurement to evaluate the clearance of both vectors in body fluids over time
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacokinetics

Over 24 weeks post infusion
Incidence of hyperammonemic episode (HAE)
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Incidence and number of hyperammonemic episodes (HAE/HAC) resulting in hospitalization
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Overall and by hospitalization severity (Mild: adjustment of dietary protein intake and oral scavenger medication / Moderate: cessation of dietary protein intake and initiation of IV scavenger therapy / Severe: requirement for hemodialysis)
時間枠:Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy.

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
Duration of hospitalization for each HAE/HAC
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Requirement for Intensive Care Unit (ICU) care during hospitalization for each HAE/HAC
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics and Efficacy

Over 24 weeks post infusion
Time to liver transplant from dosing to end of study (EOS)
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Supportive Secondary Endpoint: Efficacy

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Transplant free survival
時間枠:Time to lever transplant or any-cause death from dosing to EOS

Supportive Secondary Endpoint: Efficacy

Time to lever transplant or any-cause death from dosing to EOS
Overall survival
時間枠:Time to any-cause death from dosing to EOS

Supportive Secondary Endpoint: Efficacy

Time to any-cause death from dosing to EOS
Achieving and maintaining complete clinical response through end of study
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Over 24 weeks post infusion
Scavenger drug dose
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Over 24 weeks post infusion
Dietary protein intake g/kg/day
時間枠:Supportive Secondary: Over 24 weeks post infusion

Supportive Secondary Endpoint: Efficacy

Supportive Secondary: Over 24 weeks post infusion
Blood urea nitrogen measurements
時間枠:Over 24 weeks post infusion

Supportive Secondary Endpoint: Pharmacodynamics

Over 24 weeks post infusion

その他の成果指標

結果測定
メジャーの説明
時間枠
Clinical Response (CR) defined as reduction in baseline standard of care therapy
時間枠:Assessed at Week 24

Efficacy

Assessed at Week 24
Serum Neurofilament Light Chain
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Safety

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to AAVrh79 capsid in blood
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to hOTC transgene in blood
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Number of participants with antibodies to M2PCSK9 transgene in blood
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Incidence and time to medical management adjustments based on iECURE guidance (protein diet or scavenger medication)
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Efficacy

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Fasting plasma ammonia
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Fasting plasma citrulline and fasting plasma glutamine levels
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Serum PCSK9
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Pharmacodynamics

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary excretion of phenylacetate metabolites
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary phenylacetate (mcg/mL), urinary phenylacetylglutamine (mcg/mL), urinary phenylacetate/ phenylglutamine ratio.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary excretion of orotic acid metabolites.
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary orotic acid (mmol/ mol creatinine), urinary uracil (mmol/mol creatinine).

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Urinary nitrogen to urinary creatinine ratio.
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Urinary nitrogen to urinary creatinine ratio (mg/dL)

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Change from baseline at Week 24 post infusion in length.
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Length measured in centimeters.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Change from baseline at Week 24 post infusion in weight.
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Weight measured in kilograms.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Percent liver transduction via ISH/IF (in-situ hybridization / Immunofluorescence)"at Wk 24 collected by liver biopsy.
時間枠:The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
Assess the potential on and "off" target editing by amplicon-seq in liver tissue samples of participants who received ECUR-506.
時間枠:The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
Assess potential off-target editing with AAV vector ITR insertion by ITR-seq in liver tissue samples of participants who received ECUR-506
時間枠:The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
Assess for potential genetic changes in the liver tissue, collected by liver biopsy, through long read sequencing, in participants who have received ECUR-506
時間枠:The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.

Pharmacodynamics

The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
With an observed genetic safety signal, genetic analysis of Whole Blood DNA may be performed on samples collected and stored at screening and week 24, in the event of an observed genomic safety signal.
時間枠:Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Safety

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
Change from baseline at Week 24 post infusion in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
時間枠:Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.

Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-599; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill.

Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
Quality of Life, as measured by the Pediatric QOL inventory Infant Scale (PedsQL-IS)
時間枠:Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

Quality of Life

Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:George Diaz, M.D., Ph.D、iECURE, Inc.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年4月8日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2023年12月19日

QC基準を満たした最初の提出物

2024年2月2日

最初の投稿 (実際)

2024年2月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する